Advertisement

Stimulating Angiogenesis

  • Andreas Bikfalvi
Chapter

Abstract

Cardiovascular diseases (myocardial infarction, cerebral ischemia, or lower-limb arterial disease) contribute significantly to mortality and morbidity in our societies. These diseases are the result of arterial obstruction that consequently reduces the blood supply to the heart or to the peripheral tissues. This results in ischemia or necrosis of the tissue in question. New therapeutic approaches must therefore be developed to treat these diseases. The idea of promoting vascularization in tissues that suffer from a lack of blood supply, as is the case in myocardial infarction, stroke, and lower-limb arterial disease, is a sound strategy. The idea was to promote collateral circulation to save poorly irrigated tissue that suffers from a lack of oxygen supply (“ischemic tissue”). In the chapter on the history of angiogenesis we saw that John Hunter had already somehow anticipated this idea.

References

  1. 141.
    Berger JS, Hiatt WR (2012) Medical therapy in peripheral artery disease. Circulation 126(4):491–500. https://doi.org/10.1161/CIRCULATIONAHA.111.033886CrossRefPubMedGoogle Scholar
  2. 142.
    Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35(5):930–936CrossRefPubMedGoogle Scholar
  3. 143.
    Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH, Investigators T (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359(9323):2053–2058CrossRefPubMedGoogle Scholar
  4. 144.
    Khurana R, Simons M (2003) Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 13(3):116–122CrossRefPubMedGoogle Scholar
  5. 145.
    Fadini GP, Losordo D, Dimmeler S (2012) Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110(4):624–637. https://doi.org/10.1161/CIRCRESAHA.111.243386CrossRefPubMedPubMedCentralGoogle Scholar
  6. 146.
    Rohde E, Schallmoser K, Reinisch A, Hofmann NA, Pfeifer T, Frohlich E, Rechberger G, Lanzer G, Kratky D, Strunk D (2011) Pro-angiogenic induction of myeloid cells for therapeutic angiogenesis can induce mitogen-activated protein kinase p38-dependent foam cell formation. Cytotherapy 13(4):503–512. https://doi.org/10.3109/14653249.2010.536214CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  • Andreas Bikfalvi
    • 1
  1. 1.Angiogenesis and Tumor Microenvironment LaboratoryUniversity of Bordeaux and National Institute of Health and Medical ResearchPessacFrance

Personalised recommendations